GlobalData on MSN11h
Daiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trial
Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...
BioSpace8h
AstraZeneca and Daiichi Sankyo’s Enhertu Enhances Stomach Cancer Case With Phase III Win
The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...
pharmaphorum6h
Enhertu extends survival in advanced gastric cancer
Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...
Cure Today4h
Enhertu Associated With Survival Increase in HER2+ Metastatic Gastric Cancer
Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...
PharmiWeb8h
Imfinzi-based perioperative regimen recommended for approval in the EU by CHMP for resectable non-small cell lung cancer
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...
Pharmabiz14h
EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer
EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer ...
Pharmaceutical Technology4h
Antibody drug conjugates: Tackling the unsolved challenges with novel technologies
ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.